Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 50: 391-402, 2004; 10.1373/clinchem.2003.026799
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer, K.
Right arrow Articles by Ueland, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, K.
Right arrow Articles by Ueland, P. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:391-402.)
© 2004 American Association for Clinical Chemistry, Inc.


Automation and Analytical Techniques

High-Level Multiplex Genotyping of Polymorphisms Involved in Folate or Homocysteine Metabolism by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry

Klaus Meyer1,a, Åse Fredriksen1 and Per Magne Ueland1

1 LOCUS for Homocysteine and Related Vitamins, University of Bergen, Bergen, Norway.

aAddress correspondence to this author at: LOCUS for Homocysteine and Related Vitamins, Department of Pharmacology, University of Bergen, Armauer Hansens Hus, N-5021 Bergen, Norway. Fax 47-55-974605; e-mail klaus.meyer{at}farm.uib.no.


   Abstract
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
 
Background: Increased plasma total homocysteine (tHcy), a risk factor for cardiovascular disease, is related to genetic, environmental, and nutritional factors, in particular folate status. Future large epidemiologic studies of the genetic basis of hyperhomocysteinemia will require high-throughput assays for polymorphisms of genes related to folate and Hcy metabolism.

Method: We developed a high-level multiplex genotyping method based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the detection of 12 polymorphisms in 8 genes involved in folate or Hcy metabolism. The assay includes methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1298A>C, methionine synthase (MTR) 2756A>G, methionine synthase reductase (MTRR) 66A>G, cystathionine ß-synthase (CBS) 844ins68 and 699C>T, transcobalamin II (TCII) 776C>G and 67A>G, reduced folate carrier-1 (RFC1) 80G>A, paraoxonase-1 (PON1) 575A>G and 163T>A, and betaine homocysteine methyltransferase (BHMT) 742G>A.

Results: The failure rate of the assay was <=1.7% and was attributable to unsuccessful DNA purification, nanoliter dispensing, and spectrum calibration. Most errors were related to identification of heterozygotes as homozygotes. The mean error rate was 0.26%, and error rates differed for the various single-nucleotide polymorphisms. Identification of CBS 844ins68 was carried out by a semiquantitative approach. The throughput of the MALDI-TOF MS assay was 1152 genotypes within 20 min.

Conclusions: This high-level multiplex method is able to genotype 12 polymorphisms involved in folate or Hcy metabolism. The method is rapid and reproducible and could facilitate large-scale studies of the genetic basis of hyperhomocysteinemia and associated pathologies.


   Introduction
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
 
Increased plasma total homocysteine (tHcy)1 is an independent risk factor for cardiovascular disease (1), venous thromboembolism (2), impaired cognitive function (3), Alzheimer disease (4), and adverse pregnancy outcome (5). Hyperhomocysteinemia is caused by low intake of folate and other B vitamins and by genetic factors (6)(7), including polymorphisms of genes encoding enzymes involved in Hcy remethylation, such as methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and variants of cystathionine ß-synthase (CBS), which catalyzes the irreversible step of the transsulfuration pathway (Fig. 1 ). Single-nucleotide polymorphisms (SNPs) with documented metabolic and biological effects include MTHFR 677C>T (8), which is a strong determinant of tHcy in individuals with impaired folate status (9). The 677TT genotype has been described as an independent risk factor for cardiovascular disease, colorectal neoplasias, neural tube defects, and pregnancy complications (9). MTHFR 1298A>C (10)(11), MTR 2756A>G (12)(13)(14), MTRR 66A>G (15)(16)(17), and CBS 844ins68 (18)(19)(20)(21) have been associated with hyperhomocysteinemia, neural tube defects, and colorectal cancer. Several other polymorphisms, including CBS 1080C>T and 699C>T (22)(23), transcobalamin-II (TCII) 776C>G (24)(25)(26)(27)(28) and 67A>G (29), reduced folate carrier-1 (RFC1) 80G>A (30)(31)(32)(33), betaine homocysteine methyltransferase (BHMT) 742G>A (34)(35), and paraoxonase-1 (PON1) 575A>G and 163T>A (36)(37), have been related to folate or Hcy status, and their possible associations with risk of cardiovascular disease and other diseases are under investigation.



View larger version (45K):
[in this window]
[in a new window]
 
Figure 1. Polyorphisms included in the MALDI-TOF MS assay, and the role of the corresponding enzymes and transporters in folate or Hcy metabolism.

AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; CH2THF, methylenetetrahydrofolate; CH3THF, methyltetrahydrofolate; DMG, dimethylglycine; Cysta, cystathionine; Hcy-tl, homocysteine thiolactone; THF, tetrahydrofolate.

Traditional methods for the identification of known polymorphisms are restriction fragment-length polymorphism (RFLP) analysis, oligonucleotide ligation assay, and minisequencing (38)(39)(40)(41). These techniques usually include separation of DNA fragments by gel electrophoresis, are labor-intensive, and provide low-throughput genotyping. Non-gel-based technologies have recently been developed for rapid genotyping of large study cohorts (38)(39)(40)(41). These methods achieve allelic differentiation by hybridization, mini- and pyrosequencing, oligonucleotide ligation assay, and cleavage of a flap probe. Homogeneous or solid-phase reaction formats are used in combination with fluorescent dyes or mass spectrometry (MS) for detection. Various high-density formats have been adapted to capillary electrophoresis (42), DNA microarrays (43), bead-based assays (44), and MS (45) to obtain cost-effective genotyping by miniaturization and a high degree of multiplexing. Recent publications have described ultrahigh-throughput approaches that enable the identification of up to hundreds of thousands (46) or millions (47) of genotypes within 24h.

Generally, genotyping by MS does not require labeled primers, and mass determination provides direct molecular information. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS in particular has become a powerful tool for detection of known SNPs and mutations (48)(49) as a result of recent advances in both sample preparation and instrument performance. Such advances include better sample desalting and choice of an appropriate matrix (50)(51)(52)(53)(54). Introduction of nanoliter-volume handling (45), hydrophilic anchors (55), and chip hybridization (56) have enhanced sample throughput and reduced analysis costs. Delayed extraction has become a standard option in linear TOF instruments and offers enhanced resolution and high sensitivity (57). Minisequencing is the convenient strategy for multiplex detection of known alleles by MALDI-TOF MS. The Pin-Point (58) and the PROBE (59) formats allow simultaneous detection of up to 12 alleles (60), with use of dideoxynucleotide triphosphates (ddNTPs) or mixtures of deoxynucleotide triphosphates (dNTPs) and ddNTPs, respectively.

This report presents a fast and reliable Pin-Point assay for multiplex genotyping by MALDI-TOF MS of 12 polymorphisms related to folate or Hcy metabolism. The method detects MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G, CBS 844ins68, CBS 699C>T, BHMT 742G>A, RFC1 80G>A, TCII 67A>G, TCII 776C>G, PON1 163T>A, and PON1 575A>G. The polymorphisms included in the MALDI-TOF MS assay and the role of the corresponding enzymes and transporters in folate or homocysteine metabolism are depicted in Fig. 1Up .


   Material and Methods
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
 
dna purification and multiplex pcr
Whole blood was obtained from 460 blood donors. DNA was purified from 30 µL of blood by use of the Geno M-96 workstation (Geno Vision). The yield was 200–400 ng and according to the manufacturer’s description. The PCRs were multiplexed in two separate groups, as described in Table 1 . PCR was performed in a total volume of 25 µL containing 12 ng of template DNA, 1.25 U of HotStarTaqTM polymerase (Qiagen), 4 mM MgCl2, 1.2 µM dNTPs (Amersham Bioscience), and 0.25 µM each primer. Oligo 6.0 (Molecular Biology Insights) was used for design of primers, which were synthesized by Eurogentec. The cycling conditions (MJR Dynad thermal cycler) were 95 °C for 15 min followed by 40 cycles at 95 °C for 30 s, 66 °C (group 1) or 62 °C (group 2) for 30 s, and 72 °C for 1 min, with a final extension at 72 °C for 10 min.


View this table:
[in this window]
[in a new window]
 
Table 1. PCR primers and products for genotyping by MALDI-TOF MS.

Purification of PCR products, which removed primers and dNTPs, was carried out by incubation of 10 µL of PCR mixture with 3 µL of ExoSAP-ITTM (USB Corporation) at 37 °C for 15 min, followed by 15 min at 80 °C.

primer extension reaction
The multiplex primer extension reaction was carried out with purified PCR products as template and a mixture of 12 site-specific primers (Eurogentec; Table 2 ), which were extended by one matching ddNTP (Amersham Bioscience). The optimum primer concentrations were empirically determined and ranged from 1 to 26 pmol. The total reaction volume of 25 µL contained 5 µL of PCR product, 50 µM ddNTPs, and 4 U of ThermoSequenaseTM (Amersham Bioscience). The cycling conditions (MJR Dynad thermal cycler) were 90 cycles at 94 °C for 30 s, 62 °C for 30 s, and 72 °C for 1 min. Liquid handling was performed in 96-sample format on a Biomek 2000 Workstation (Beckman Coulter).


View this table:
[in this window]
[in a new window]
 
Table 2. Extension primers for genotyping by MALDI-TOF MS.

comparison methods
Two different techniques were used to verify the MALDI-TOF MS results. MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, and MTRR 66A>G were genotyped by a TaqMan real-time PCR assay, as described previously (61). RFLP analysis was used to identify BHMT 742G>A (35), CBS 699C>T (22), PON1 163T>A, PON1 575A>G, RFC1 80G>A (32), TCII 776C>G, and TCII 67A>G (29). PCRs were performed in a total volume of 25 µL containing 12 ng of template DNA, 1.25 U of HotStarTaq polymerase, 1.5 mM MgCl2, 0.48 µM dNTPs, and 0.5 µM each PCR primer. Assay conditions, including primers, are listed in Table 3 . Because the sequence contexts of BHMT 742G>A, CBS 699C>T, and TCII 776C>G did not include a restriction site, primers were designed to introduce an artificial restriction site.


View this table:
[in this window]
[in a new window]
 
Table 3. PCR primers and restriction enzymes for the comparison method based on RFLP analysis.

Each PCR product (10 µL) was digested with 10–15 U of restriction enzyme (Table 3Up ) for 12 h and analyzed by gel electrophoresis. CBS 844ins68 was identified by gel electrophoresis without previous restriction enzyme cleavage.

preparation of samples for maldi-tof ms
AG 50W-X8 resin (Bio-Rad) was activated by incubation in a solution of 1 mol/L ammonium acetate (Sigma Aldrich) and then washed five times with deionized water. Ammonia solution (ultrapure; Merck) was then used to adjust the pH of the resin to ~9. The products from minisequencing reactions were incubated for at least 1 h with resin to remove salt adducts. Homogeneous crystallization was achieved by dispensing nanoliter samples on silicon chips (SpectroChipTM; Sequenom) prespotted with formulated MALDI matrix. The robot, equipped with four piezoelectric pipettes, dispensed 8 nL of sample at the positions of each hydrophilic anchor of the chip holding 96 samples.

maldi-tof ms
A ReflexTM III (Bruker Daltonik) was used for MALDI-TOF MS. The spectrometer was equipped with a nitrogen laser emitting at 337 nm with an 8 Hz pulse rate. The SCOUTTM 384 ion source was run in positive linear ion mode at 25 kV. To avoid detector saturation from matrix ions, masses <4000 Da were suppressed by detector gating. MALDI-TOF MS analyses were run fully automated by fuzzy-logic instrument control, and the numbers of shots per spectrum were 30 or 50 (2 x 25).

data processing
XMASSTM software (Bruker) was used to automate spectrum processing and genotype identification. Spectra were calibrated by linear regression using three oligo(A) nucleotides (15A, 23A, and 30A) as internal standards. Background subtraction and data smoothing preceded peak registration. For all detected peaks, intensities relative to the highest peak in the observed mass range were determined. Signal cutoff was set at a relative intensity of 0.15. The mass window used for signal identification was ±6 Da of the theoretical mass. If data processing detected a peak doublet, the ratio between the signals was calculated to distinguish heterozygous from homozygous samples. The threshold values for the ratio were determined empirically, and doublets were identified as heterozygous if the ratio was between 0.56 and 1.8.

assay validation
The accuracy of the assay was evaluated in terms of failure rate and error rate, which were determined by no-calls and discrepant calls, respectively. Two experiments were carried out. In the first experiment, 368 samples were genotyped by MALDI-TOF MS, and the results for MTHFR 677C>T were verified by the real-time PCR assay. In the second experiment, all SNPs were identified in 92 samples by both the MALDI-TOF MS and by the comparison methods. Sample deposition on chips and MALDI-TOF MS analyses were repeated seven times to assess the performance of the MALDI-TOF procedure. In both experiments, we determined the failure and error rates attributable to each step in the protocol and for all SNPs.

identification of CBS 844INS68
The CBS 844ins68 polymorphism is a duplication of 68 bp from intron 7 and exon 8 into exon 8, with changes of 4 bases in the inserted sequence (http://www.uchsc.edu/sm/cbs/cbsdata/ins68.htm). The entire wild-type sequence is also present in the allele containing the insertion. Therefore, a semiquantitative approach was applied to achieve unambiguous allele determination. A unique site inside the insertion was used to distinguish between the wild-type sequence and insertion by probe extension. The ratios between insertion and origin were 0:2 in wild-type, 1:2 in heterozygous, and 2:2 in homozygous individuals.


   Results
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
 
maldi-tof ms spectra
The differences in masses of the four ddNTPs (ddA, 297.21 Da; ddC, 273.19 Da; ddG, 313.21 Da; ddT, 288.20 Da) are the molecular basis for identification of genotypes. Fig. 2 shows the spectra of the 12 extension primers and their single-base extension products. Most of the peaks could be assigned to extension products, and only two signals were unextended primers. The mass difference of the heterozygous signals varied between 9 (ddA/ddT) and 40 Da (ddC/ddG), depending of the incorporated base. The heterozygous extension products of PON1 163T>A had the only peak doublet, with a 9-Da difference, and was clearly distinguished. Sodium adducts and depurination products in the spectrum were minor and did not interfere with assignment of genotype.



View larger version (34K):
[in this window]
[in a new window]
 
Figure 2. MALDI-TOF MS analysis of 12 polymorphisms.

The top panel shows a spectrum of the extension primers before reaction. Twelve probes were distributed over a mass range of 4500–9500 Da. The concentrations were adjusted to achieve similar signal intensities over the entire mass range. Three oligo(A) nucleotides were included for internal mass calibration. The bottom panel shows the extended primers obtained by genotyping a real sample. Nearly all primers were consumed. The inset shows the peak of the PON1 163TA doublet corresponding to a mass difference of 9 Da. Spectra were acquired in positive linear ion mode.

assay validation and performance
Analysis of the MTHFR 677C>T genotypes.
In the first experiments, 368 samples were genotyped for the MTHFR 677C>T polymorphism by MALDI-TOF MS and real-time PCR. The total failure rate of the MALDI-TOF MS assay was 1.7%. Failures were related to preparation of DNA (1.1%), nanoliter dispensing (0.3%), and mass calibration (0.3%). PCR, primer extension, and spectrum acquisition were without failures (Table 4 ).


View this table:
[in this window]
[in a new window]
 
Table 4. Failures attributable to sample preparation and MS.

The three variants of the MTHFR 677C>T polymorphism were clearly distinguished by MALDI-TOF MS as shown in the scatter plot of allele signal intensities in Fig. 3 . The mean ratio of the 677CT cluster was 0.85, which demonstrates that allele signals were not equal. For a few homozygous calls, a minor signal corresponding to the other allele was detected, and such spurious signals were observed both in the TT and CC sectors (Fig. 3 ). Furthermore, one homozygous wild-type call by the MALDI-TOF MS assay was identified as heterozygous by the real-time PCR assay.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 3. Relative allele signal intensities of the MTHFR 677C>T polymorphism by MALDI-TOF MS.

The relative intensities of the MTHFR 677C>T allele signals were plotted for 368 DNA samples. The x axis depicts the intensities of the C allele, and the y axis the intensities of the T allele. Three sectors were empirically defined for classification of the variants. The cluster of the heterozygous 677CT genotype had a mean signal ratio of 0.85. One sample in the sector of 677CC (marked X) was identified as heterozygous by the comparison method and was a discrepant call. Signals with relative intensities below a threshold of 0.15 (dashed lines) were recorded as no signal.

Replicate analysis of 11 SNPs by MALDI-TOF MS.
In the second experiment, all SNPs were identified in 92 samples by comparison methods. DNA purification, PCR, and primer extension worked without failure (Table 4Up ). All 92 samples were carried through the final steps, including the nanoliter dispensing and MALDI-TOF MS analyses, seven times to get an accurate assessment of the performance of the MALDI-TOF procedure. These experiments demonstrated that spectrum acquisition was without failure. The nanoliter dispensing and mass calibration showed 9 failure rates (0.3%) equal to those found in the first experiment (Table 4Up ). Thus, the total failure rate was 0.6%.

All discrepancies were related to misinterpretation of heterozygous signals. The errors were attributable to detection of only one peak of the doublets, resulting from insufficient peak resolution; low mass accuracy; or suppression of signal from one allele (Table 5 ). We observed 18 discrepant calls, corresponding to an overall error rate of 0.26%. Of these, 14 (78%) were attributable to insufficient peak quality (mass resolution and accuracy) and 4 (22%) to unequal allele signals (Table 5 ).


View this table:
[in this window]
[in a new window]
 
Table 5. Discrepant calls of heterozygous genotypes (error rate) attributable to quality of spectrum obtained by MALDI-TOF MS.1

Insufficient peak resolution and mass accuracy of the heterozygous signals were essentially confined to two SNPs, PON1 163T>A and PON1 575A>G. PON1 163TA produced four and PON1 575AG produced six discrepant calls, which were related to insufficient resolution of one peak within each doublet (Table 5Up ).

The standard variation of the allele signal ratio for seven replicates of one sample was determined for the MTHFR 677CT genotype and was 15%.

We analyzed 92 samples by MALDI-TOF MS, applying 50 shots (2 x 25 shots) and 30 shots per sample. Errors were again caused by underestimation of heterozygotes, and the rates were 0.4% at 50 shots and 1.5% at 30 shots. At 50 shots per spectrum, peak broadening by spectrum summation led to insufficient mass resolution, which explained most discrepant calls. The 30-shot spectra suffered from lower signal intensities, which caused both insufficient mass resolution and unequal signal intensities for heterozygous doublets (data not shown).

Spectrum acquisition of one chip (holding 96 samples) required ~20 min at 50 shots per sample and 10 min at 30 shots per sample.

identification of CBS 844INS68
The theoretical peak-intensity ratio of the mutant to wild-type alleles by MALDI-TOF MS is 0.5 for heterozygotes and 1 for homozygotes (Fig. 4A ). Three experiments were carried out to determine the actual threshold for the peak-intensity ratios allowing differentiation of the three genotypes by MALDI-TOF MS.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 4. Determination of CBS 844ins68 by quantitative MALDI-TOF MS.

(A), graphic presentation of the positions of the 68-bp insertion and extension primers. (B), ratios between the signal intensities for the two CBS alleles in heterozygous (n = 88) and homozygous (n = 2) samples identified by genotyping 368 samples by RFLP analysis. The signal-intensity ratios obtained from these 368 DNA samples by MALDI-TOF MS were plotted in the left panel. Both homozygotes were clearly resolved from the heterozygotes. The right panel shows the allele signal ratios of the 2 homozygous and 20 heterozygous samples subjected to seven repetitive analyses. Differentiation between the two variants was again obtained at a signal-ratio threshold of ~0.8. Samples with relative signal intensities below a threshold of 0.25 (dashed lines) were classified as wild type.

We first genotyped 92 samples by both the conventional comparison methods and MALDI-TOF MS. A threshold of 0.25 for the ratio of mutant to wild-type alleles distinguished heterozygous from homozygous wild-type samples. The observed error rate was 1.2%.

We then analyzed 368 samples by MALDI-TOF MS; 92 samples had peak-intensity ratios above the threshold of 0.25. Of these samples, 2 (2.1%) were identified as homozygous wild type, 2 as homozygous mutant, and 88 as heterozygous by the comparison method. All heterozygous samples had peak intensity ratios <0.8, whereas the 2 homozygotes had ratios >0.8 (Fig. 4BUp ).

In a last experiment, we analyzed the 2 homozygous and 20 of the heterozygous samples seven times by MALDI-TOF MS. The peak ratios are plotted in the right-hand panel of Fig. 4BUp . A signal ratio of 0.8 was again found to differentiate between heterozygotes and homozygotes.


   Discussion
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
 
We report the development and application of a MALDI-TOF MS assay based on multiplex primer extension for the simultaneous determination of 12 polymorphisms in genes encoding enzymes involved in folate or Hcy metabolism. The method is rapid and allows unambiguous identification of 11 SNPs. CBS 844ins68 was successfully determined by a semiquantitative approach.

pcr and primer extension reaction
The high level of multiplexing in PCR and primer extension required appropriate primer analysis software and empirical optimization to obtain primer compatibility and equal annealing temperatures. In the present assay, the multiplex PCR had to be divided into two separate reactions, whereas the extension primers worked satisfactorily in a single reaction.

The useful mass range of 4000–9000 Da of the TOF MS impacts the design and concentration of minisequencing primers. Fine adjustment of primer concentrations was necessary to obtain similar signal intensities over the entire mass range because sensitivity decreases with mass in TOF MS. The resolving power also decreases with increasing mass; therefore, extension primers creating a heterozygous doublet with a small mass difference should be placed in the lower mass range. This is the case for PON1 163T>A, which produced a doublet with a difference of 9 Da (difference between A and T). The extension primer for this SNP was assigned a mass of ~5500 Da (Fig. 1Up ).

Multiplexing >12 SNPs would be desirable in clinical and population studies. However, a higher degree of multiplexing is restricted by the design of site-specific extension probes, which must be arranged in a limited mass range. Expanding the mass range beyond 4000–10 000 Da is essentially impossible, because shorter primers with <15 bases lead to lower priming efficiency, whereas longer primers are detected with decreased sensitivity and resolution in MALDI-TOF MS.

preparation of samples for maldi-tof ms
Analysis of oligonucleotides by MALDI-TOF MS is sensitive to the presence of metal contamination (62). The presence of metal cations, e.g., Na+, produces adducts, leading to peak broadening, reduced resolution, and low sensitivity. Various sample desalting procedures have been established for DNA analyses by MALDI-TOF MS (54)(63)(64). We used cation-exchange beads as an effective and inexpensive means for desalting low-molecular-weight oligonucleotides. Incubation for 1 h was sufficient to obtain spectra with essentially no cation adducts. Depurination of oligonucleotides is also a potential problem and occurs most frequently at low pH (65). Therefore, resin beads were washed repeatedly before use to remove excess ammonium acetate, but depurination products were still observed occasionally in some MALDI-TOF spectra. A final adjustment of the beads to pH 9 prevented depurination in all analyses.

3-Hydroxypicolinic acid is a widely used matrix for DNA analysis because it provides limited fragmentation (50). However, nonhomogeneous crystallization is obtained with the classic dried droplet preparation, and a search for "hot" spots is required (45). Moreover, mass resolution and accuracy are related to topography of large matrix crystals with a size in the millimeter range. Chip-based nanoliter dispensing on hydrophilic anchors allowed robust and controlled, high-density formation of small single crystals. This miniaturized sample preparation combined with fuzzy-logic-controlled MALDI analysis provided reproducible spectra of high quality.

failure rates
The maximum failure rate is given in Table 4Up . Summation of the highest rates observed in both experiments leads to a failure of <=1.4% attributable to unsuccessful DNA preparation and nanoliter dispensing. Wrong mass calibration increased the failure rate to <=1.7%, but spectra were easily recalibrated. Multiplex PCR, multiplex primer extension, and spectrum acquisition were without failure and, therefore, the most robust steps of the assay.

error rates
All discrepant calls were caused by incorrect identification of heterozygotes as homozygotes. Low peak quality (insufficient mass resolution, low mass accuracy) occasionally hampered the detection of one of the alleles within a heterozygous doublet, and such mistakes explained the majority (14 of 18) of all errors. In particular, PON1 163TA and 575AG gave more discrepant calls than the other SNPs (Table 5Up ). Low resolution of the PON1 163TA doublet hindered identification in spite of the primer being placed in the lower mass range. In addition, PON1 575AG gave insufficient peak resolution, which was related to the high mass of the extension primer.

A second explanation for incorrect identification of heterozygotes is the inequality of allele signals within the same SNP, which explained 22% (4 of 18) of errors (Table 5Up ). This unbalance has a statistical and systematic component. Repetitive analyses of MTHFR 677CT demonstrated a variation in the peak ratio of 15%, which may be related to nonhomogeneous distribution of the two extended primers. A systematic disparity was also observed for MTHFR 677C>T (Fig. 3Up ). The mean peak ratio in a heterozygous sample was 0.85 and may be related to preferential incorporation of one dideoxynucleotide and/or allele-specific differences in desorption/ionization probabilities.

success rate
The maximum failure rate (<=1.7%) and the mean error rate (0.26%) give a total success rate of >98%, which demonstrates accurate SNP genotyping by the MALDI-TOF MS method described here. The performance is comparable to or better than that of MALDI-TOF MS SNP analyses published by others (66)(67)(68). Duplicate analysis and comparison of simultaneously prepared chips are recommended to identify discrepant calls and may further improve the performance of the assay.

CBS 844INS68 polymorphism
The CBS 844ins68 polymorphism consists of the insertion of 68 bp from intron 7 and exon 8 into exon 8 (69). The wild-type sequence is present in all alleles. Therefore, unambiguous differentiation of heterozygotes from homozygotes by primer extension required a semiquantitative approach. This further demonstrates the quantitative ability of MALDI-TOF MS, which previously has been exploited for the assessment of SNP prevalences in pooled samples (70)(71).

The number of samples homozygous for 844ins68 was too low to determine the exact measurement error, but at this stage, this approach is potentially useful for identifying samples for confirmatory genotyping by conventional methods. Additional work is necessary to determine the accuracy of the MALDI-TOF MS assay for 844ins68.

throughput
Acquisition of MALDI-TOF MS spectra for one sample takes <15 s. At a rate of 50 shots/sample, the mean sampling time was 12 s/sample. A lower shot number to increase throughput is not recommended because the error rate would increase significantly. Upgrading the MALDI-TOF MS to a higher laser pulse rate would enhance the throughput without decreasing accuracy. The overall assay throughput of two 96-microtiter plates per day could be further increased by implementing a fully automated 384-sample format for sample preparation.

In conclusion, we have developed an assay for polymorphisms, based on MALDI-TOF MS. The assay is based on allele-specific extension to achieve allelic differentiation and is characterized by a high degree of multiplexing. Eleven SNPs (MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G, CBS 699C>T, BHMT 742G>A, RFC1 80G>A, TCII 67A>G, TCII 776C>G, PON1 163T>A, and PON1 575A>G) and 1 insertion polymorphism (CBS 844ins68) are included. The assay thus exploits the multiplexing potential, the resolving power, and the quantitative features of the MALDI-TOF platform. All of the polymorphisms measured are involved in folate or Hcy metabolism. Therefore, the assay represents a potentially valuable tool for large population-based studies on the biological role of polymorphisms related to one-carbon metabolism.


   Acknowledgments
 
We are grateful to Rita Skålevik for excellent technical assistance and Arve Ulvik for valuable discussions. This work was supported by the Foundation to Promote Research into Functional Vitamin B12 Deficiency.


   Footnotes
 
1 Nonstandard abbreviations: Hcy, homocysteine; MTHFR, methylenetetrahydrofolate reductase; BHMT, betaine-homocysteine methyltransferase; MTR, methionine synthase; MTRR, methionine synthase reductase; CBS, cystathionine ß-synthase; SNP, single-nucleotide polymorphism; TCII, transcobalamin II; RFC1, reduced folate carrier-1; PON1, paraoxonase-1; RFLP, restriction fragment-length polymorphism; MS, mass spectrometry; MALDI-TOF; matrix-assisted laser desorption/ionization time of flight; ddNTP, dideoxynucleotide triphosphate; and dNTP, deoxynucleotide triphosphate.


   References
Top
Abstract
Introduction
Material and Methods
Results
Discussion
References
 

  1. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  2. den Heijer M, Keijzer MB. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med 2001;39:710-713.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  3. Delport R. Hyperhomocyst(e)inemia, related vitamins and dementias. J Nutr Health Aging 2000;4:195-196.[Medline] [Order article via Infotrieve]
  4. Miller JW. Homocysteine and Alzheimer’s disease. Nutr Rev 1999;57:126-129.[Web of Science][Medline] [Order article via Infotrieve]
  5. Refsum H. Folate, vitamin B12 and homocysteine in relation to birth defects and pregnancy outcome. Br J Nutr 2001;85(Suppl 2):S109-S113.
  6. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.[Abstract/Free Full Text]
  7. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences?. Q J Med 1993;86:685-689.[Web of Science][Medline] [Order article via Infotrieve]
  8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  9. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.[CrossRef][Medline] [Order article via Infotrieve]
  10. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-172.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  11. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 1998;62:1044-1051.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  12. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999;84:151-157.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  13. Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999;17:298-309.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  14. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:825-829.[Abstract/Free Full Text]
  15. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-323.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  16. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 2000;7:197-200.[Web of Science][Medline] [Order article via Infotrieve]
  17. Gaughan DJ, Kluijtmans LA, Barbaux S, McMaster D, Young IS, Yarnell JW, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001;157:451-456.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  18. Speer MC, Nye J, McLone D, Worley G, Melvin EC, Viles KD, et al. Possible interaction of genotypes at cystathionine ß-synthase and methylenetetrahydrofolate reductase (MTHFR) in neural tube defects. NTD Collaborative Group. Clin Genet 1999;56:142-144.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  19. Tsai MY, Yang F, Bignell M, Aras O, Hanson NQ. Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine ß-synthase gene, and pyridoxal-5'-phosphate concentration. Mol Genet Metab 1999;67:352-356.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  20. de Franchis R, Fermo I, Mazzola G, Sebastio G, Di Minno G, Coppola A, et al. Contribution of the cystathionine ß-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000;84:576-582.[Web of Science][Medline] [Order article via Infotrieve]
  21. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002;13:239-248.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  22. Kruger WD, Evans AA, Wang L, Malinow MR, Duell PB, Anderson PH, et al. Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. Mol Genet Metab 2000;70:53-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  23. Aras O, Hanson NQ, Yang F, Tsai MY. Influence of 699C->T and 1080C->T polymorphisms of the cystathionine ß-synthase gene on plasma homocysteine levels. Clin Genet 2000;58:455-459.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  24. McCaddon A, Blennow K, Hudson P, Regland B, Hill D. Transcobalamin polymorphism and homocysteine. Blood 2001;98:3497-3499.[Free Full Text]
  25. Namour F, Olivier J, Abdelmouttaleb I, Adjalla C, Debard R, Salvat C, et al. Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. Blood 2001;97:1092-1098.[Abstract/Free Full Text]
  26. Afman LA, Lievers KJ, Van Der Put NM, Trijbels FJ, Blom HJ. Single nucleotide polymorphisms in the transcobalamin gene: relationship with transcobalamin concentrations and risk for neural tube defects. Eur J Hum Genet 2002;10:433-438.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  27. Miller JW, Ramos MI, Garrod MG, Flynn MA, Green R. Transcobalamin II 775G>C polymorphism and indices of vitamin B12 status in healthy older adults. Blood 2002;100:718-720.[Abstract/Free Full Text]
  28. Zetterberg H, Regland B, Palmer M, Rymo L, Zafiropoulos A, Arvanitis DA, et al. The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion. Hum Reprod 2002;17:3033-3036.[Abstract/Free Full Text]
  29. Lievers KJA, Afman LA, Kluijtmans LAJ, Boers GHJ, Verhoef P, den Heijer M, et al. Polymorphisms in the transcobalamin gene: associations with homocysteine concentrations and cardiovascular disease risk. Clin Chem 2002;48:1383-1389.[Abstract/Free Full Text]
  30. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70:310-315.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  31. De Marco P, Calevo MG, Moroni A, Arata L, Merello E, Cama A, et al. Polymorphisms in genes involved in folate metabolism as risk factors for NTDs. Eur J Pediatr Surg 2001;11(Suppl 1):S14-S17.
  32. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002;108:1-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  33. De Marco P, Calevo MG, Moroni A, Merello E, Raso A, Finnell RH, et al. Reduced folate carrier polymorphism (80A->G) and neural tube defects. Eur J Hum Genet 2003;11:245-252.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  34. Morin I, Platt R, Weisberg I, Sabbaghian N, Wu Q, Garrow TA, et al. Common variant in betaine-homocysteine methyltransferase (BHMT) and risk for spina bifida. Am J Med Genet 2003;119A:172-176.
  35. Weisberg IS, Park E, Ballman KV, Berger P, Nunn M, Suh DS, et al. Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis 2003;167:205-214.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  36. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 2001;491:35-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  37. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln->Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002;33:1459-1464.[Abstract/Free Full Text]
  38. Kwok PY. High-throughput genotyping assay approaches. Pharmacogenomics 2000;1:95-100.[CrossRef][Medline] [Order article via Infotrieve]
  39. Larsen LA, Christiansen M, Vuust J, Andersen PS. Recent developments in high-throughput mutation screening. Pharmacogenomics 2001;2:387-399.[CrossRef][Medline] [Order article via Infotrieve]
  40. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 2001;47:164-172.[Abstract/Free Full Text]
  41. Tsuchihashi Z, Dracopoli NC. Progress in high throughput SNP genotyping methods. Pharmacogenomics J 2002;2:103-110.[CrossRef][Medline] [Order article via Infotrieve]
  42. Medintz IL, Paegel BM, Blazej RG, Emrich CA, Berti L, Scherer JR, et al. High-performance genetic analysis using microfabricated capillary array electrophoresis microplates. Electrophoresis 2001;22:3845-3856.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  43. Dong S, Wang E, Hsie L, Cao Y, Chen X, Gingeras TR. Flexible use of high-density oligonucleotide arrays for single-nucleotide polymorphism discovery and validation. Genome Res 2001;11:1418-1424.[Abstract/Free Full Text]
  44. Michael KL, Taylor LC, Schultz SL, Walt DR. Randomly ordered addressable high-density optical sensor arrays. Anal Chem 1998;70:1242-1248.[Medline] [Order article via Infotrieve]
  45. Little DP, Cornish TJ, O‘Donnel MJ, Braun A, Cotter RJ, Köster H. MALDI on a chip: analysis of arrays of low-femtomole to subfemtomole quantities of synthetic oligonucleotides and DNA diagnostic products by a piezoelectric pipet. Anal Chem 1997;69:4540-4546.[CrossRef]
  46. Bell PA, Chaturvedi S, Gelfand CA, Huang CY, Kochersperger M, Kopla R, et al. SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery [Erratum published in Biotechniques 2003;34:496]. Biotechniques 2002;(Suppl):70-72,74,76–7.
  47. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: a SNP linkage disequilibrium Map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques 2002;(Suppl):48-50,52,54.
  48. Sauer S, Gut IG. Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2002;782:73-87.[Web of Science][Medline] [Order article via Infotrieve]
  49. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by mass spectrometry. Mass Spectrom Rev 2002;21:388-418.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  50. Wu KJ, Steding A, Becker CH. Matrix-assisted laser desorption time-of-flight mass spectrometry of oligonucleotides using 3-hydroxypicoline acid as an ultraviolet-sensitive matrix. Rapid Commun. Mass Spectrom 1993;7:142-146.
  51. Lecchi P, Le HM, Pannell LK. 6-Aza-2-thiothymine: a matrix for MALDI spectra of oligonucleotides. Nucleic Acids Res 1995;23:1276-1277.[Free Full Text]
  52. Zhu YF, Chung CN, Taranenko NI, Allman SL, Martin SA, Haff L, et al. The study of 2,3,4-trihydroxyacetophenone and 2,4,6-trihydroxyacetophenone as matrices for DNA detection in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1996;10:383-388.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  53. Li YCL, Cheng S-W, Chan TWD. Evaluation of ammonium salts as co-matrices for matrix-assisted laser desorption/ionization mass spectrometry of oligonucleotides. Rapid Commun Mass Spectrom 1998;12:993-998.[CrossRef]
  54. Ragas JA, Simmons TA, Limbach PA. A comparative study on methods of optimal sample preparation for the analysis of oligonucleotides by matrix-assisted laser desorption/ionization mass spectrometry. Analyst 2000;125:575-581.[CrossRef][Medline] [Order article via Infotrieve]
  55. Schuerenberg M, Luebbert C, Eickhoff H, Kalkum M, Lehrach H, Nordhoff E. Prestructured MALDI-MS sample supports. Anal Chem 2000;72:3436-3442.[Medline] [Order article via Infotrieve]
  56. Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Koster H. Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A 1999;96:10016-10020.[Abstract/Free Full Text]
  57. Juhasz P, Roskey MT, Smirnov IP, Haff LA, Vestal ML, Martin SA. Applications of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry to oligonucleotide analysis. Anal Chem 1996;68:941-946.[Medline] [Order article via Infotrieve]
  58. Haff LA, Smirnov IP. Single-nucleotide polymorphism identification assays using a thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. Genome Res 1997;7:378-388.[Abstract/Free Full Text]
  59. Braun A, Little DP, Köster H. Detecting CFTR gene mutations by using primer oligo base extension and mass spectrometry. Clin Chem 1997;43:1151-1158.[Abstract/Free Full Text]
  60. Ross P, Hall L, Smirnov I, Haff L. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol 1998;16:1347-1351.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  61. Ulvik A, Ueland PM. Single nucleotide polymorphism (SNP) genotyping in unprocessed whole blood and serum by real-time PCR: application to SNPs affecting homocysteine and folate metabolism. Clin Chem 2001;47:2050-2053.[Free Full Text]
  62. Nordhoff E, Ingendoh A, Cramer R, Overberg A, Stahl B, Karas M, et al. Matrix-assisted laser desorption/ionization mass spectrometry of nucleic acids with wavelengths in the ultraviolet and infrared. Rapid Commun Mass Spectrom 1992;6:771-776.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  63. Gilar M, Blenky A, Wang BH. High-throughput biopolymer desalting by solid-phase extraction prior to mass spectrometric analysis. J. Chromatogr A 2001;921:3-13.[CrossRef]
  64. Smirnov IP, Hall LR, Ross PL, Haff LA. Application of DNA-binding polymers for preparation of DNA for analysis by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2001;15:1427-1432.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  65. Barnes WM. PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. Proc Natl Acad Sci U S A 1994;91:2216-2220.[Abstract/Free Full Text]
  66. Bray MS, Boerwinkle E, Doris PA. High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat 2001;17:296-304.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  67. Lechner D, Lathrop GM, Gut IG. Large-scale genotyping by mass spectrometry: experience, advances and obstacles. Curr Opin Chem Biol 2002;6:31-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  68. Nakai K, Habano W, Fujita T, Schnackenberg J, Kawazoe K, Suwabe A, et al. Highly multiplexed genotyping of coronary artery disease-associated SNPs using MALDI-TOF mass spectrometry. Hum Mutat 2002;20:133-138.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  69. Sperandeo MP, de Franchis R, Andria G, Sebastio G. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine ß-synthase mRNA. Am J Hum Genet 1996;59:1391-1393.[Web of Science][Medline] [Order article via Infotrieve]
  70. Ross P, Hall L, Haff LA. Quantitative approach to single-nucleotide polymorphism analysis using MALDI-TOF mass spectrometry. Biotechniques 2000;29:620-626, 628–9.[Web of Science][Medline] [Order article via Infotrieve]
  71. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A 2001;98:581-584.[Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. J.P.M. Eussen, S. E. Vollset, S. Hustad, O. Midttun, K. Meyer, A. Fredriksen, P. M. Ueland, M. Jenab, N. Slimani, P. Ferrari, et al.
Vitamins B2 and B6 and Genetic Polymorphisms Related to One-Carbon Metabolism as Risk Factors for Gastric Adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition
Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 28 - 38.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
W. Thongnoppakhun, S. Jiemsup, S. Yongkiettrakul, C. Kanjanakorn, C. Limwongse, P. Wilairat, A. Vanasant, N. Rungroj, and P.-t. Yenchitsomanus
Simple, Efficient, and Cost-Effective Multiplex Genotyping with Matrix Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of Hemoglobin Beta Gene Mutations
J. Mol. Diagn., July 1, 2009; 11(4): 334 - 346.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
Y. Lamers, J. Williamson, M. Ralat, E. P. Quinlivan, L. R. Gilbert, C. Keeling, R. D. Stevens, C. B. Newgard, P. M. Ueland, K. Meyer, et al.
Moderate Dietary Vitamin B-6 Restriction Raises Plasma Glycine and Cystathionine Concentrations While Minimally Affecting the Rates of Glycine Turnover and Glycine Cleavage in Healthy Men and Women
J. Nutr., March 1, 2009; 139(3): 452 - 460.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
K. Meyer, A. Fredriksen, and P. M. Ueland
MALDI-TOF MS Genotyping of Polymorphisms Related to 1-Carbon Metabolism Using Common and Mass-Modified Terminators
Clin. Chem., January 1, 2009; 55(1): 139 - 149.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. E. Vollset, J. Igland, M. Jenab, A. Fredriksen, K. Meyer, S. Eussen, H. K. Gjessing, P. M. Ueland, G. Pera, N. Sala, et al.
The Association of Gastric Cancer Risk with Plasma Folate, Cobalamin, and Methylenetetrahydrofolate Reductase Polymorphisms in the European Prospective Investigation into Cancer and Nutrition
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2416 - 2424.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. D Niculescu, K.-A. da Costa, L. M Fischer, and S. H Zeisel
Lymphocyte gene expression in subjects fed a low-choline diet differs between those who develop organ dysfunction and those who do not
Am. J. Clinical Nutrition, July 1, 2007; 86(1): 230 - 239.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Misra, J.-Y. Hong, and S. Kim
Multiplex Genotyping of Cytochrome P450 Single-Nucleotide Polymorphisms by Use of MALDI-TOF Mass Spectrometry
Clin. Chem., May 1, 2007; 53(5): 933 - 939.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. K. Blievernicht, E. Schaeffeler, K. Klein, M. Eichelbaum, M. Schwab, and U. M. Zanger
MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms
Clin. Chem., January 1, 2007; 53(1): 24 - 33.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K.-A. da Costa, O. G. Kozyreva, J. Song, J. A. Galanko, L. M. Fischer, and S. H. Zeisel
Common genetic polymorphisms affect the human requirement for the nutrient choline
FASEB J, July 1, 2006; 20(9): 1336 - 1344.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Kohlmeier, K.-A. da Costa, L. M. Fischer, and S. H. Zeisel
Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans
PNAS, November 1, 2005; 102(44): 16025 - 16030.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
N. Ghebranious, L. Ivacic, J. Mallum, and C. Dokken
Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology
Nucleic Acids Res., October 4, 2005; 33(17): e149 - e149.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
M. Boniotto, M. H. Hazbon, W. J. Jordan, G. P. Lennon, J. Eskdale, D. Alland, and G. Gallagher
Novel Hairpin-Shaped Primer Assay To Study the Association of the -44 Single-Nucleotide Polymorphism of the DEFB1 Gene with Early-Onset Periodontal Disease
Clin. Vaccine Immunol., July 1, 2004; 11(4): 766 - 769.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer, K.
Right arrow Articles by Ueland, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, K.
Right arrow Articles by Ueland, P. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Automation and Analytical Techniques


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS